Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap82.74B
Enterprise Value83.28B
Trailing P/E18.74
Forward P/E18.17
REGN
(NASDAQ)Regeneron Pharmaceuticals, Inc.
$761.85-- (--)
Loading... - Market loading
Regeneron Pharmaceuticals (REGN) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)5.89
Forward Price/Sales5.83
Price/Book (mrq)2.70
Price/Tangible Book (mrq)2.81
Price/FCF (ttm)22.42
Price/OCF (ttm)16.95
PEG Ratio8.96
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue5.81
EV/Earnings18.49
EV/EBITDA14.31
EV/EBIT15.79
EV/FCF22.12
Stock Price
Current price, 52-week range, and moving averages
Current Price$761.85
1-Day Change0.60%
52-Week High$821.11
52-Week Low$476.49
52-Week Change25.97%
YTD Change0.12%
1-Year Change24.24%
50-Day MA$765.25
200-Day MA$661.52
Avg Volume (30 day)999.68K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding108.60M
Book Value per Share$287.82
Net Cash per Share$28.71
FCF per Share$34.67
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$854.83
Target Upside/Downside12.20%
Analyst ConsensusBuy
Analyst Count12
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin85.35%
EBITDA Margin (ttm)40.57%
EBIT Margin (ttm)36.77%
Operating Margin (ttm)25.66%
Pretax Margin (ttm)36.47%
Profit Margin (ttm)31.41%
FCF Margin (ttm)26.25%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)14.41%
Return on Assets (ttm)11.11%
Return on Invested Capital (ttm)15.08%
Return on Capital Employed (ttm)14.57%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue14.34B
Gross Profit12.24B
Operating Income3.68B
Pretax Income5.23B
Net Income4.50B
EBITDA5.82B
EBIT5.27B
Diluted EPS$41.91
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow4.98B
Capital Expenditures1.21B
Free Cash Flow3.77B
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth0.99%
Dividend Growth306.82%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)40.56B
Cash & Securities (mrq)3.12B
Net Cash (mrq)3.12B
Net Cash per Share$28.71
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)1.99B
Working Capital (mrq)13.65B
Total Equity (mrq)31.26B
Book Value per Share$287.82
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)4.13
Quick Ratio (mrq)3.39
Debt/Equity (mrq)0.06
Debt/EBITDA (ttm)0.34
Debt/FCF (ttm)0.53
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$3.58
Dividend Yield0.46%
Payout Ratio (Earnings)8.54%
Payout Ratio (FCF)10.33%
Dividend Growth (YoY)306.82%
Ex-Dividend DateFeb 20, 2026
Pay DateMar 5, 2026
Dividend FrequencyQuarterly
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield5.34%
FCF Yield4.46%
Buyback Yield4.70%
Total Shareholder Yield5.16%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score7.87
Piotroski F-Score5/9
Dividend Score37.25
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Lynch Fair Value$87.65
Lynch Upside/Downside-88.72%
Graham Number$520.94
Graham Upside/Downside-32.98%
Frequently Asked Questions About Regeneron Pharmaceuticals Statistics
What are the key financial metrics for REGN?
Regeneron Pharmaceuticals, Inc. (REGN) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is REGN's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Regeneron Pharmaceuticals is overvalued or undervalued.
How do I read REGN's profitability ratios?
Regeneron Pharmaceuticals's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do REGN's debt ratios indicate?
The financial health section shows Regeneron Pharmaceuticals's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is REGN's dividend analysis?
The dividend section covers Regeneron Pharmaceuticals's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.